PAHC · Phibro Animal Health Corp
$37.79
+0.55 (+1.48%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.40B
Shares
40.60M
Volume · Oct 5
68.59K
Avg daily vol (3M)
238.26K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$37.24
Open$36.19
Day$36.19–37.62
52W close$28.52–59.58
Avg vol 30d261K
Short int1.1M · 2.8% float · 4.9d
Short vol66%
Last earningsAug 27, 2026
DataJan 2020–Oct 2026
Filing10-K · Aug 26
Up next
Next earnings call
Nov 26, 2026
Est · unconfirmed
· in 7 wks
filed Aug 26, 2026
call held May 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-4.5%
Trailing year
Short interest
2.8%
Latest settlement · 4.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+4%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
28%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−38%
trailing
YTD return
0%
this year
Relative strength
−50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $36 › 200d $41 — 200d above 50d
Institutional flow
Flat
1 of 208 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.81% of float · ▼ -5.5% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
208 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
Gross margin
62%
expanding
EPS growth
+104%
Y/Y
Valuation
P/E 14.2
below peers
Balance sheet
$563.6M
net debt
Quant / Vol
risk profile
Volatility
54%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
3.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 26, 2026
Diluted EPS
· year ending June 30, 2027
Initiated
$2.98 – $3.22
prior FY $2.43
midpoint +27.6% Y/Y
Adjusted EBITDA
· year ending June 30, 2027
Initiated
$258M – $268M
Adjusted net income
· year ending June 30, 2027
Initiated
$140M – $147M
Adjusted diluted EPS
· year ending June 30, 2027
Initiated
$3.41 – $3.59
Adjusted effective income tax rate
· year ending June 30, 2027
Initiated
20%
Guided vs delivered
· last 6 settled
Diluted EPS
year ending June 30, 2023
guided $0.84 – $0.94
$0.81
Miss −9.0%
Net sales
full year fiscal year 2022
guided $890M – $920M
$942.26M
Beat +4.1%
Diluted earnings per share
fiscal year 2022
guided $1.11 – $1.16
$1.21
Beat +6.6%
Diluted EPS
third quarter
guided $0.27 – $0.30
$1.34
Beat +370.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+4%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
28%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $36 › 200d $41 — 200d above 50d
Institutional flow
Flat
1 of 208 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.81% of float · ▼ -5.5% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
208 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $29
Now $37 · 28%
Range high $60
vs 200-day avg -10%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings per share non-GAAP | $3.22 | the year | — |
| Adjusted EBITDA non-GAAP | $255M | FY2026 | — |
| Adjusted EBITDA - Animal Health segment non-GAAP | $304M | fiscal 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net sales 1.16B
-692.53M Cost of goods sold
-213.38M Selling, general and administrative expenses
+46.27M Add: Depreciation and amortization
+1.96M Add: Acquisition-related cost of goods sold
+0K Add: Phibro Forward income growth initiatives implementation costs - cost of goods sold
+0K Add: Phibro Forward income growth initiatives implementation costs - SG&A
-954K Subtract: Insurance proceeds
= Adjusted EBITDA - Animal Health 303.58M
|
|||
| Adjusted EBITDA - Corporate non-GAAP | -$78M | fiscal 2026 filing | — |
| Adjusted EBITDA - Mineral Nutrition segment non-GAAP | $22M | fiscal 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net sales 282.34M
-255.66M Cost of goods sold
-7.22M Selling, general and administrative expenses
+2.21M Add: Depreciation and amortization
= Adjusted EBITDA - Mineral Nutrition 21.67M
|
|||
| Adjusted EBITDA - Performance Products non-GAAP | 8.06M | the year ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net sales 73.53M
-57.38M Cost of goods sold
-9.06M Selling, general and administrative expenses
+966K Add: Depreciation and amortization
= Adjusted EBITDA - Performance Products 8.06M
|
|||
| Adjusted EBITDA as a percentage of segment net sales - Total non-GAAP | 16.8% | the year ended June 30, 2026 filing | — |
| Adjusted EBITDA – Total segments non-GAAP | $333.31M | For the Year Ended June 30, 2026 filing | — |
| Adjusted net income non-GAAP | $131.7M | the year ended June 30, 2026 | — |
| EBITDA non-GAAP | 233.29M | the year ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income 99.72M
+44.43M Interest expense, net
+37.63M Provision for income taxes
+51.51M Depreciation and amortization
= EBITDA 233.29M
|
|||
| Free cash flow | $9.9M | twelve months ended June 30, 2026 | — |
| MFAs and other sales to poultry industry | 39% | fiscal year 2026 filing | — |
| Net sales from operations outside the United States (percentage of net sales) | 42% | the year ended June 30, 2026 filing | — |
| Sales of Mecadox (carbadox) | 21M | the year ended June 30, 2026 filing | — |
| Sales of virginiamycin in Brazil | 27M | the year ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PAHC
this stock
Phibro Animal Health Corp
|
$1.40B | -0.3% | +4.1% | 14.2 | 2.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PAHC | +8.1% | -3.5% | -37.5% | +4.2% | -0.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +8.3% | -3.0% | -49.7% | +3.3% | -13.2% |